NCT04862780 2025-02-10(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLCBlueprint Medicines CorporationPhase 1 Terminated177 enrolled
NCT02954523 2024-07-05Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR MutationsGeorgetown UniversityPhase 1/2 Terminated10 enrolled 15 charts
NCT05153408 2023-06-18(HARMONY) Study of BLU-701 in EGFR-mutant NSCLCBlueprint Medicines CorporationPhase 1 Terminated20 enrolled